Navigation Links
Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
Date:6/22/2013

igher with glimepiride versus linagliptin in each quartile of HbA1c change from baseline (all p<0.0001). The percentage of people who experienced hypoglycemia was not increased with greater reductions in HbA1c in either group. In all four-week intervals, the percentage of people who experienced a hypoglycemic event was lower with linagliptin versus glimepiride.1

About the Studies
Findings from the first exploratory analysis of data on elderly people with T2D (n=247; mean age, 74 years; baseline HbA1c, 8.2 percent) who had linagliptin or placebo added onto basal insulin therapy (baseline dose 36 U/day) from two phase III studies of 24 and > 52 weeks. The analysis measured the relative ORs for overall and confirmed hypoglycemia (the latter defined as blood glucose < 70 mg/dL). The insulin doses did not change notably throughout the trials.1

The findings from the second analysis are based on two-year data from a randomized, double-blind study of linagliptin 5 mg qd (n=777) versus glimepiride 1 mg to 4 mg qd (n=775) in people with T2D previously uncontrolled with metformin therapy.2 The study showed comparable reductions in HbA1c between the two treatments.2 For the exploratory analysis, the risk of investigator-reported hypoglycemia for linagliptin was compared with glimepiride based on dose, over time, and by HbA1c reduction. People randomized to glimepiride started treatment on 1 mg. Those who did not achieve a fasting plasma glucose level of 110 mg/dL at 4 weeks and who were not at hypoglycemia risk were subsequently uptitrated stepwise up to a maximum of 4 mg qd.2

Linagliptin, which is marketed as Tradjenta® (linagliptin) tablets in the U.S., is a once-daily 5 mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Linagliptin should not be u
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
2. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. National Brain Tumor Society Responds to Results of Avastin Clinical Trials
5. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
6. GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results
7. CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
8. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
9. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
10. Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
11. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
(Date:7/10/2014)... WASHINGTON D.C., June 17, 2014 Using microscopic ... of specific gases, researchers at MIT,s Quantum Photonics ... detection levels in the parts-per-billion range. Optical sensors ... to their high signal-to-noise ratio, compact, lightweight nature, ... optical gas sensors had been developed before, the ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... Inc. (Nasdaq:,NVAX) Novavax today announced Chief Executive Officer Dr. ... Conference at,5:05 am Eastern time (11:05 am CEST) on ... the company announced today., Dr. Singhvi will provide ... and its unique manufacturing solution. A,link to an audio ...
... Pharmaceuticals,Corp. (Nasdaq: MEMY ) today reported its ... 2008., "We had a productive start to ... our operations to advance four high-value,programs," said Vaughn ... decision to license R3487/MEM 3454 highlights the potential,of ...
... CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech ... it has,received a letter of approval from ... (MHRA) for its Clinical Trial Application (CTA),to ... intravenous administration of,REOLYSIN(R) in combination with paclitaxel ...
Cached Biology Technology:Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... good grade, or promotion wonderfully concentrates the mind, ... responsible for such reward-motivated learning. , In an ... Adcock and colleagues report brain-scanning studies in humans ... the brain's learning and memory regions to promote ...
... by the University of California, Berkeley, and Lawrence Berkeley National ... cells that can be flipped on and off as easily ... like these could trigger a chemical reaction, initiate a muscle ... all at the flash of a light. , One ...
... molecular denominator in aging and many age-related diseases is oxidative ... HMS associate professor of pathology. The skin of a bitten ... in some ways that is a good metaphor for the ... types of cells over time. , Humans and other organisms ...
Cached Biology News:The brain's motivation station 2Light-sensitive photoswitches could restore sight to those with macular degeneration 2Light-sensitive photoswitches could restore sight to those with macular degeneration 3Free radical cell death switch identified 2
... SizeSep 400 Spun Columns, 10. *SizeSep 400 ... > 400 base pairs in length. ... CL-4B and pre-equilibrated in distilled water containing 0.15% ... than ~ 400 base pairs. *Extremely ...
... 25 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... are complete ready-to-use reagents for the isolation ... specifically formulated for the isolation of genomic ... specifically formulated for the isolation of genomic ... DNAzol Reagents can be used for restriction ...
Apoptosis Detection Systems and Reagents...
Biology Products: